The Multiple Myeloma Research Foundation (MMRF) was founded in 1998 by identical twin sisters Kathy Giusti and Karen Andrews shortly following Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to
urgently and aggressively fund research that will lead to the development of new treatments for multiple myeloma.
As the world's number-one funder of multiple myeloma research, the MMRF has raised nearly $100 million to fund 70 laboratories worldwide. The payback on our investment has been significant:
Four new treatments—Thalomid, Velcade, Revlimid and Doxil—approved in four years alone when it usually takes nearly 10 years to bring a single treatment to market. These breakthrough treatments are extending the lives of myeloma patients worldwide and are now being explored in a range of other cancers, including ovarian cancer, breast cancer, prostate cancer, leukemia, and Non-Hodgkin's lymphoma
30 MMRF-supported compounds now in pre-clinical studies and clinical trials
The MMRF is one of the most effective and efficient organizations of its kind, as evidenced by our
exceptional accreditations. In 2007, nearly 93% of every dollar of revenue raised was directed toward myeloma research and related educational programs.
The MMRF's approach, with a focus on speed, innovation, and results, is widely recognized across the medical and scientific communities, as well as by several
prominent publications, as an optimal model to accelerate medical research and drug development across various cancers and diseases.
